Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $3.9 million.

  • Q32 Bio's Accumulated Expenses fell 5618.27% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 5618.27%. This contributed to the annual value of $7.5 million for FY2024, which is 2339.44% down from last year.
  • According to the latest figures from Q3 2025, Q32 Bio's Accumulated Expenses is $3.9 million, which was down 5618.27% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Q32 Bio's Accumulated Expenses registered a high of $19.8 million during Q1 2024, and its lowest value of $3.9 million during Q3 2025.
  • Its 5-year average for Accumulated Expenses is $10.9 million, with a median of $10.0 million in 2021.
  • As far as peak fluctuations go, Q32 Bio's Accumulated Expenses soared by 10440.78% in 2023, and later crashed by 7344.26% in 2025.
  • Quarter analysis of 5 years shows Q32 Bio's Accumulated Expenses stood at $11.4 million in 2021, then soared by 64.08% to $18.7 million in 2022, then plummeted by 47.83% to $9.8 million in 2023, then decreased by 23.39% to $7.5 million in 2024, then plummeted by 47.79% to $3.9 million in 2025.
  • Its Accumulated Expenses stands at $3.9 million for Q3 2025, versus $4.4 million for Q2 2025 and $5.3 million for Q1 2025.